JPRN-UMIN000009184已完成2 期
Multi-institutional phase II study of photodynamic therapy using ME2906 and PNL6405EPG for patients with local failure after chemoradiotherapy for esophageal cancer - Investigator initiated clinical trial of PDT for esophageal cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) patients with lymph node or distant metastasis with indication for systemic chemotherapy 2) active malignancy at other organs, except for cancer which are unnecessary to be treated with systemic treatment within 6 months, or curable cancer with local treatment 3) significant cardiovascular diseases (uncontrolled hypertension, myocardial infarction, unstable angina, congestive heart failure), uncontrolled diabetes mellitus, or severe liver cirrhosis, severe renal failure 4)severe systemic infection 5) judged by investigator that inability to obey the sun shade restrictions 6) baseline lesions before CRT or RT judged to involve the aorta 7) porphyria 8) additional PDT just after salvage endoscopic mucosal resection or endoscopic submucosal dissection for local failures 9) preexisting of sun photosensitivity 10) history of treatment with PDT using porfimer sodium or talaporfin sodium 11) pregnant or nursed women, or unwillingness to use of contraception 12) Severe bleeding or shock status 13) tendency of hemorrhage 14) participating in other clinical trials or within 3 months after retirement of prior clinical trial, 15) judged by investigator that enrollment was inappropriate for the patient.
研究者
相似试验
招募中
2 期
Multi-institutional phase II study of photodynamic therapy using ME2906 and PNL6405SCT for patients with malignant spinal cord tumor.spinal cord malignant tumorMalignancyD013120JPRN-jRCT2021220040Endo Toshiki20
进行中（未招募）
不适用
A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancerEUCTR2006-004857-86-FRCaprion Pharmaceuticals Inc.40
进行中（未招募）
不适用
Study of the clinical activity and safety of vemurafenib (PLX-4032) in previously treated patients with hairy cell leukemia carrying the BRAF-V600E mutatioHairy cell leukemia (HCL)carrying the BRAF-V600 mutationMedDRA version: 14.1Level: PTClassification code 10019053Term: Hairy cell leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005487-13-ITIVERSITA' DEGLI STUDI DI PERUGIA
未知
2 期
PhaseII/III double-blind comparative study of the efficacy and safety of TAK-536CCB when coadministered with hydrochlorothiazide in patients with grade I or II essential hypertensioHypertensionJPRN-jRCT2080221917TAKEDA PHARMACEUTICAL COMPANY LTD.
进行中（未招募）
不适用
A Study of RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 MutatioMetastatic or unresectable papillary thyroid cancer positive for BRAF V600 mutation and resistant to radioactive iodine therapyMedDRA version: 14.1Level: LLTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024133-23-ITF. Hoffman-La Roche Ltd.40